The vaccine was described as "promising" after 85 per cent of women with a ductal carcinoma in situ (DCIS) - the most common non-invasive form of the disease - were still showing protection after four years.
Researchers at the University of Pennsylvania in the United States enrolled 27 patients and isolated specialised white cells using standard techniques similar to blood donation.
The cells were manipulated in the laboratory to allow the immune system to recognise the cancerous cells as foreign and attack them.
Each patient received four weekly injections of their personalised vaccine and had surgery two weeks later to remove any remaining disease.
The study, published in the Journal of Immunotherapy, compared pre-vaccination samples with post-vaccination samples and found five patients, almost 20 per cent, had no disease visible, indicating their immune system had wiped out the tumour.